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Abstract
BORIS/CTCFL is a member of cancer testis antigen family normally expressed in germ cells. In tumors, it is aberrantly
expressed although its functions are not completely well-defined. To better understand the functions of BORIS in cancer, we
selected the embryonic cancer cells as a model. Using a molecular beacon, which specifically targets BORIS mRNA, we
demonstrated that BORIS positive cells are a small subpopulation of tumor cells (3–5% of total). The BORIS-positive cells
isolated using BORIS-molecular beacon, expressed higher telomerase hTERT, stem cell (NANOG, OCT4, SOX2) and cancer
stem cell marker genes (CD44 and ALDH1) compared to the BORIS-negative tumor cells. In order to define the functional role
of BORIS, stable BORIS-depleted embryonic cancer cells were generated. BORIS silencing strongly down-regulated the
expression of hTERT, stem cell and cancer stem cell marker genes. Moreover, the BORIS knockdown increased cellular
senescence in embryonic cancer cells, revealing a putative role of BORIS in the senescence biological program. Our data
indicate an association of BORIS expressing cells subpopulation with the expression of stemness genes, highlighting the
critical role played by BORIS in embryonic neoplastic disease.
Citation: Alberti L, Renaud S, Losi L, Leyvraz S, Benhattar J (2014) High Expression of hTERT and Stemness Genes in BORIS/CTCFL Positive Cells Isolated from
Embryonic Cancer Cells. PLoS ONE 9(10): e109921. doi:10.1371/journal.pone.0109921
Editor: Gabriele Saretzki, University of Newcastle, United Kingdom
Received June 20, 2014; Accepted September 12, 2014; Published October 3, 2014
Copyright:  2014 Alberti et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its
Supporting Information files.
Funding: This research was supported by the Swiss National Science Foundation (grant number: 31003A-113505; www.snf.ch); and Emma Muschamp
Foundation (www.s-a-v.org/-Fondations-associees-.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation
of the manuscript.
Competing Interests: One of the authors (JB) is employed by a molecular pathology laboratory (Biopath Lab). This does not alter the authors’ adherence to
PLOS ONE policies on sharing data and materials.
* Email: jean.benhattar@gmail.com
Introduction
Brother of the regulator of imprinting sites (BORIS) also
designed as CTCFL, CCCTC-binding factor-like, is a DNA-
binding protein with functions in cancer not fully understood.
CTCF is a highly conserved, ubiquitously expressed, multifunc-
tional chromatin factor that plays a role as a tumor suppressor
gene [1–3]. BORIS is a mammalian paralog of CTCF, they share
the same 11 zinc-finger domain but differ at N- and C- termini.
Within this zinc-finger domain, BORIS and CTCF exhibit 70% of
homology [4]. In normal tissues, BORIS expression is restricted to
germ cells, where it is involved in epigenetic reprogramming [4,5].
BORIS is expressed in spermatocytes during male germ line
development, apparently in absence of CTCF [4]. In tumors,
BORIS is aberrantly expressed and its transcription was detected
at different levels in several cancer cell lines and in primary tumors
[6]. Due to its restricted expression in normal germinal tissues and
its re-expression in a wide variety of tumors, BORIS belongs to
cancer testis antigen (CTA) family. It has been shown that BORIS
induced expression of other CTA genes, as MAGE-A1, NY-ESO-
1 [7,8] and SPANX [9] but not in all tumors [10,11]. In addition,
we previously showed that BORIS activated hTERT expression by
binding to the first exon of the hTERT telomerase gene in
embryonic and ovarian tumor cells [12]. Furthermore, in studies
of exogenous BORIS expression in normal BORIS-negative cells,
we demonstrated that these transfected cells exhibited high levels
of hTERT mRNA [12]. All these results revealed an important
role of BORIS in the immortalization process during tumorigen-
esis. Interestingly, current reports show a correlation between
hTERT expression and stem cell-like properties [13–17]. Further
investigations regarding the correlation between BORIS functions
and the main roles of hTERT in the immortalization and stemness
properties have to be performed. Another question not yet clearly
answered is how many cells, within a tumor cell line, express
BORIS. In this paper, we address these questions. For this
purpose, we selected to use the molecular beacon (MB) imaging
technology, as it is an approved method to detect and also to
visualize mRNA expression [18]. MBs are oligonucleotides
structured as stem-loop hairpin with a fluorescence quencher at
one end and, at the opposite end, a fluorescent dye also called
fluorophore. Due to their specific structure, MBs emit fluorescence
signals only when binding to their targets. To explore the
frequency of BORIS-positive cells within tumor cell lines, we first
designed a BORIS mRNA targeting MB, and then we analyzed
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BORIS expression in human embryonic and ovarian tumor cell
lines, respectively NCCIT and OVCAR3. After verifying that
BORIS-MB enable FACS sorting of BORIS-positive cells, we
showed that the isolated BORIS-positive cells expressed higher
mRNA level of hTERT and stemness genes compared to BORIS-
negative and non-sorted NCCIT cells. We further confirmed this
result by BORIS silencing studies. Moreover, we showed that
BORIS protects from senescence process. Altogether, our data
confirm a direct role of BORIS in embryonic neoplastic disease.
Materials and Methods
Cells
The human cell lines (BJ, foreskin fibroblast; HeLa, cervical
adenocarcinoma; NCCIT, embryonic carcinoma; OVCAR3,
ovary carcinoma) were purchased from the American Type
Culture Collection (ATCC). The cells were cultured at 37uC with
5% CO2 either in Dulbecco’s modified Eagle’s medium (DMEM;
Gibco, Invitrogen) for HeLa and BJ cells, or in RPMI-1640
medium (Gibco, Invitrogen) for NCCIT and OVCAR3, supple-
mented with 10% of heat inactivated fetal bovine serum
(Invitrogen) and 1% of Penicillin-Streptomycin (Gibco, Invitro-
gen).
Molecular beacon (MB) design
Sequences of BORIS-MB1 and BORIS-MB2 were designed
using Beacon Designer (Premier Biosoft). BORIS mRNA second-
ary structures were predicted using mFOLD software (mFOLD,
http://www.bioinfo.rpi.edu/applications/mfold/) and specificity
was determined by BLAST search (NCBI). The target sequence of
BORIS-MB1 is located on exon 2 and that of BORIS-MB2 is
located on exon 11 of BORIS mRNA. These locations were
chosen since they are outside the zinc-finger domain and do not
cross-hybridize with the CTCF homology regions. In addition,
previous study has shown that the starting and the ending regions
of mRNA are the more accessible for MBs hybridization [19]. The
RANDOM-MB that was used as negative control does not match
with any mammalian sequences [19]. Sequences were the
following: BORIS-MB1 59-CGCTGTCTCTGCACACTCCGT-
CTTCAGCG-39; BORIS-MB2 59-CAGCCATTCCTCTTTGA-
CTCTGGCTG-39 and RANDOM-MB 59-CGACGCGACAAG-
CGCACCGATACGTCG-39 (underlined bases indicating those
complementary to the target sequences). A fluorophore (Cy3 or
ATTO647) was 59-conjugated and a Black Hole Quencher (BHQ-
2) was linked to the 39-end. The MBs were purchased from Sigma
and they were purified by high-pressure liquid chromatography.
In vitro determination of MB specificity
Oligos were designed to be specific of the MBs targets (BORIS-
MB1 specific target: 59-AAGACGGAGTGTGCAGAGAGA-39;
BORIS-MB2 specific target: 59-CAGCCAGAGTCAAAGAG-
GAA-39 and RANDOM-MB specific target: 59-TATCGGTG-
CGCTTGTCG-39). A non-specific oligo was used for the in vitro
test of the different MBs. This non-specific oligo, 59-CGATGCC-
GAACCAATTCTCCAC-39, corresponds to a transcript variant
of CTCF. To test the specificity in solution, 200 nM of MB was
mixed or not with 1 mM of oligo in 10 mL of Opti-MEM medium
(Invitrogen).
The emission fluorescence profiles were obtained after heating
the MB-target oligo mix to a progressive temperature elevation
ranging from 15 to 80uC using 1uC steps. Fluorescence signal was
acquired at the end of each increasing degree and detected on the
Cy3 channel using a Rotor Gene 6000 Real-Time PCR system
(Corbett Life Science).
MB delivery and cell fluorescence imaging
Cells were detached using 0.05% trypsin-EDTA (Invitrogen)
and resuspended in serum-free DMEM medium at the concen-
tration of 106 cells/ml. Firstly, Cy3-BORIS-MB or Cy3-RAN-
DOM-MB (200 nM) was incubated at room temperature in
presence of 1 ml/ml of Lipofectamine RNAiMAX siRNA trans-
fection reagent (Invitrogen) using Opti-MEM medium. The
Lipofectamine RNAiMAX reagent was used as delivery vehicle
since in our conditions it gave less background compared to other
reagents such as Streptolysin (data not shown). After 10 min, the
transfection mix was added to the suspended cells and together
incubated for 1 hour at 37uC. Hoechst 33342 (Invitrogen) was
added at concentration of 5 mg/mL during the last 10 min of
incubation. Then, cells were washed using Phosphate Buffered
Saline (PBS, Invitrogen) and resuspended in PBS with 5 mM
EDTA. Transfected cells were cytocentrifugated onto glass slide
using a cytospin centrifuge and examined under fluorescent
microscope (Axioplan2 Imaging, Zeiss). The fluorescence signal of
Cy3-coniugated MB was analyzed using the red channel and
Hoechst 33342 fluorescence emission was observed under blue
channel.
FACS analysis and sorting using MB
For FACS analysis and cell sorting, we used MBs conjugated
with ATTO 647, a dye characterized by its high photostability
[20]. Cells were prepared and incubated with MBs as described
above (except that Hoechst 33342 was not added) and were
directly analyzed using Gallios flow cytometer (Beckman Coulter).
At least 10,000 events were collected and analyzed by Kaluza
Software. The BORIS-positive and BORIS-negative populations
were sorted after exclusion of dead cells by Propidium Iodide (PI)
staining using FACSAria I (Becton Dickinson) instrument at the
Flow Cytometry Facility of UNIL (University of Lausanne,
Switzerland). Ranges of 26104–96104 BORIS-positive cells and
26105–96105 BORIS-negative cells were sorted.
BORIS knockdown by inducible shRNA lentiviral system
Stable cell lines with inducible expressing shRNAs targeting
human BORIS mRNA were generated using the doxycycline-
inducible shRNA lentiviral system, pINDUCER [21]. The
lentiviral vector pINDUCER11 constitutively expresses the eGFP
fluorescent reporter protein, which enables to track cells trans-
duced by the virus. This vector also contains a cassette with a
doxycycline-inducible promoter that controls the transcription of a
tRFP reporter gene together with the shRNA, which allows
detection of cells with doxycycline activated shRNA transcription
[21]. Four different shRNAmiR (shRNA) specifically targeting
BORIS, and not its parolog CTCF (BORIS-sh1: 59-ATTCAC-
CAAGATCAAAGAACTC-39, BORIS-sh2: 59-GTTCTCACA-
GTTTCAAATTCAA-39, BORIS-sh3: 59-TTCATCCCGACT-
GTTTACAAAT-39, BORIS-sh4: 59TCCGACAGAAGCAACT-
TCTAAA-39) and a control shRNA with scrambled sequence
(CTR sh: 59CAGAGCTAACTCAGATAGTACT39) were
synthetized (Sigma). They were PCR amplified and cloned into
the pINDUCER11 backbone using EcoRI and XhoI restriction
enzymes. The sequences of all constructs were verified by
sequencing. Lentivirus were generated by co-transfection of the
appropriate shRNA constructs along with the packaging vectors
(pMD2G-VSVg, pCMV-dR8.74) into HEK-293T cells using
FuGENE 6 reagent (Roche Diagnostics) according to the
manufacturer’s protocol. Viral supernatants were harvested
48 hours after transfection, filtered through a 0.45 mm pore filter,
ultracentrifugated for 1.5 hours at 19,500 rpm in a Beckman
SW28 rotor and resuspended in RPMI medium. The viral
BORIS/CTCFL in Embryonic Cancer Cells
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suspension combined with 8 mg/ml polybrene (Sigma) was used to
infect target cells (NCCIT). Twenty-four hours post infection the
medium was replaced and stably infected cells were eGFP-sorted
using FACSAria I instrument (Becton Dickinson) at the Flow
Cytometry Facility of UNIL. Induction of shRNA expression was
obtained by addition to the medium of 2 mg/ml of doxycycline
(Sigma). To maintain the knockdown, doxycycline-containing
medium was refreshed every 3 days.
Ectopic BORIS expression in HeLa cells
The day prior transfection, HeLa cells were seeded at a density
of 26105 cells/well in 12-well/plates. Cells were transfected with
3 mg of the previously described pCMV-BORIS vector [12] using
the Lipofectamine 2000 transfection reagent (Invitrogen) following
the manufacturer’s instructions. Cells were harvested 2 days post-
transfection for cell fluorescence imaging.
Quantitative RT-PCR
Total RNA was isolated using the RNeasy mini kit (Qiagen)
including on-column DNAse treatment according to the manu-
facturer’s instructions. RNA concentration was determined using
Nanodrop 2000 (Thermo Scientific) and Qubit Fluorescent
Technology (Invitrogen).
A major limiting step was the low amount of total RNA isolated
from cell sorting. To solve this technical limitation, we applied a
method already described and validated [22,23]. Firstly, 200 ng of
total RNA were retrotranscribed using random hexamers and
Superscript III reverse transcriptase (Invitrogen) in a final volume
of 20 ml. Then 2 ml of cDNA were used for a preamplification
reaction consisting on a multiplex PCR made with a mix of
primers (Table S1) at 0.1 mM final concentration, 0.5 unit of
Platinum Taq DNA Polymerase (Invitrogen), 1X PCR buffer, and
2 mM MgCl2 in a total volume of 25 ml.
For preamplification, PCR cycling conditions were: one
denaturation step at 95uC for 5 min followed by 15 cycles of
amplification (45 sec at 95uC, 30 sec at 60uC, 1 min at 72uC).
Finally, for quantitative PCR, the preamplification reaction was
20-fold diluted and 2 ml of this dilution were used as template.
Reaction was complemented with 0.5 units Platinum Taq DNA
Polymerase (Invitrogen), 1X PCR buffer, 2.5 mM MgCl2, 2.5 mM
SYTO9 green (Invitrogen) and 0.1 mM of each gene specific
primer (Sigma) in a final volume of 20 ml. PCR conditions were:
95uC for 5 min followed by cycles (5 sec at 95uC, 30 sec at 60uC,
45 sec at 72uC). Melting curve analyses were performed at the end
of the amplification to check the purity of the amplicons. The PCR
products were also loaded on agarose gel to confirm the correct
size of amplified products. Cycling and fluorescence acquisition
were done in Rotor-Gene 6000 Real-Time PCR system (Corbett
Life Science). Data analysis was performed using Rotor-Gene
6000 software. Relative expression levels were determined by
DDCt method with expression levels normalized to GAPDH level.
The PCR efficiency ranged from 94 to 101%, with correlation
coefficient (r2) ranging from 0.96 to 1.0, for all the amplified target
genes. The Ct values of GAPDH were roughly the same
(Ct = 10.0760.25) for all the cells used in the quantitative RT-
PCR experiments.
The human specific primers (Table S1) were designed using
Primer3 (http://bioinfo.ut.ee/primer3-0.4.0/) and OLIGO Prim-
er Analysis software. Specificity was verified using BLAST search
(NCBI). The designed primer pairs cross intron-exon boundaries
to avoid genomic DNA contamination. BORIS primers were
chosen (between exon 8 and 9) based on results previously
obtained [24] in order to amplify the most abundant BORIS
isoforms.
DNA methylation analysis
DNA was extracted using DNeasy kit (Qiagen). A range of
200 ng (from sorted cells) and 500 ng of DNA was used to bisulfite
reaction using EpiTect Bisulfite kit (Qiagen) according to the
manufacturer’s instructions. The modified DNA was used to
amplify a 123 bp fragment of the BORIS promoter.
The methylation assay was designed using the PyroMark Assay
Design Software 1.0 (Qiagen). This assay allowed sequencing of
50 bp (from position 2968 to 2918) inside the promoter B of
BORIS [25] and included 10 CpG. To perform sequencing, 3 ml
of bisulfite treated DNA were first amplified by PCR. Sequences of
the PCR primers were: BORIS-pyro Forward 59 TGGTTTG-
TGGGTTTTGT 39 and BORIS-pyro BIO Reverse 59 CCCT-
TCACCCCCCCTCTTT 39. PCR conditions were as follow:
95uC for 5 min; 45 cycles of 95uC for 30 s, 58uC for 15 s and
72uC for 1 min; and a final extension step at 72uC for 10 min.
Then, purification and subsequent processing of the biotinylated
single-stranded PCR fragment were performed according to the
manufacturer’s recommendations. Pyrosequencing of this PCR
fragment was performed on a PyroMark Q24 instrument using
Pyro Gold Q24 Reagents (Qiagen). The pyrosequencing primer
(59 GTGTTGTAGTTTATAGT 39) was used at a final concen-
tration of 0.3 mM. Resulting data were analyzed and quantified
with the PyroMark Q24 software (Qiagen) which calculates the
methylation percentage for each CpG site, allowing quantitative
comparisons.
Cell proliferation assay
Cell proliferation was assessed by MTT assay. MTT (3-(4,5-
dimethyl-2-thiazol)-2,5-diphenyltetrazolium bromide, Sigma) re-
agent was used according to the manufacturer’s instructions.
Briefly, stably infected cells were seeded at a density of
256103 cells/well in 24-well/plates with doxycycline-containing
medium. After 3 days, cells were incubated with MTT reagent
(200 mg/ml final concentration) for 3 hours at 37uC. Then, cells
were lysed adding isopropanol/HCl for 10 min and the plates
were gently shaken for 5 min. Absorbance values were determined
using a microplate reader (Synergy Mx, BioTek) at 570 nm. Each
experiment was performed in triplicate and 3 independent
experiments were conducted.
Apoptosis analysis
Apoptosis was measured in triplicates using Annexin V
Apoptosis Detection Kit (BD bioscience) according to the
manufacturer’s protocols. Briefly, 56104 cells/well were seeded
in 12-well/plates and were grown in presence of doxycycline until
confluence (5–7 days). The floating cells as well as trypsinized cells
were collected, washed with PBS and resuspended in 100 ml
Binding Buffer. Then, 5 ml of Annexin V-V500 and 5 ml of 7AAD
were added and incubated with the cells for 30 min at room
temperature. After addition of 400 ml of Binding Buffer the
samples were immediately analyzed by Gallios flow cytometer
(Beckman Coulter). At least 56104 events were counted for all
samples. The percentage of apoptotic cells was estimated after
gating on eGFP and tRFP (transduced and doxycycline-induced,
respectively) positive cells.
Western blot analysis
Whole cell lysates were obtained using RIPA buffer (Sigma) in
presence of protease inhibitor cocktail (Sigma) and quantified
using the BCA assay (Thermo Scientific). Thirty micrograms of
protein were loaded on a 10% SDS-polyacrylamide gel, followed
by blotting on a nitrocellulose membrane using a semi-dry transfer
BORIS/CTCFL in Embryonic Cancer Cells
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apparatus (BIO RAD). Non-specific binding was blocked by
overnight incubation in 5% non-fat dried milk in TBS-T buffer
(0.1% Tween 20 in tris-buffered saline, TBS) at 4uC. The
membranes were then probed with monoclonal mouse anti-
human BORIS/CTCFL antibody (produced and kindly provided
by Dr Dmitri Loukinov, NIH/NIAD) used at 1:1000 dilution in
1% blocking buffer (1% low-fat dried milk in TBS-T buffer) and
incubated at room temperature for 1.5 hours. As loading control,
mouse anti-human b-actin antibody (Sigma) at 1:5000 dilution in
1% blocking buffer was used and incubated at room temperature
for 45 min. The membranes were washed 36 with TBS-T and
incubated at room temperature for 1 hour with horseradish
peroxidase (HRP)-labeled rabbit anti-mouse IgG (Sigma) diluted
at 1:5000 in 5% blocking buffer. After 36washing with TBS-T,
the membranes were developed using WesternBright Quantum
(Advansta) and visualized with Fusion FX Chemiluminescence
System (Vilber Lourmat).
Senescence-associated b-Galactosidase staining
Senescence-associated b-galactosidase (SA-b-gal) staining was
performed using b-galactosidase staining kit (BioVision), according
to the manufacturer’s instructions. Briefly, 56104 cells/well were
seeded in 12-well/plates in presence of doxycycline and were
grown until confluence (5–7 days). Then, cells were rinsed with
PBS, fixed for 15 min and incubated with freshly prepared SA-b-
Gal staining solution at 37uC for 24 hour. After washing with PBS,
SA-b-gal activity was observed using inverted microscope (Nikon)
by detection of blue stained cells. At least 10 separate fields were
selected. For each field the number of blue stained cells and the
number of total cells were counted. Results are expressed as
percentage of SA-b-gal-positive cells calculated as: (number of blue
cells/number of total cells) x 100.
Telomerase activity
Telomerase activity was measured using TRAPEZE RT
telomerase detection kit (Millipore). This assay quantifies telomerase
activity by SYBR Green real-time quantitative PCR [26]. Briefly,
cells were lysed in 200 ml of CHAPS buffer and protein
concentrations were determined with Nanodrop 2000. Aliquots of
cell lysate (1.5 mg of protein/sample) were used. Inactivated
samples, no-template reactions, and positive control were also
assayed for quality control. A standard curve was prepared by serial
dilution of TSR8 control template following manufacturer’s
instructions. Real-time amplifications were performed using Plati-
num Taq DNA Polymerase (2 unit/sample, Invitrogen). Cycling
and fluorescence acquisition were done in Rotor Gene 6000 real-
time PCR system (Corbett Life Science). Telomerase activity was
calculated by comparing the average Ct values from each sample
against the standard curve generated by the TSR8 control template.
Statistical analysis
Statistical significance was evaluated using two-tailed student t-
test analysis. P-value ,0.05 was considered statistically significant.
Results
In vitro validation of the molecular beacons (MBs)
Two different MBs specific to BORIS mRNA (BORIS-MB1
and BORIS-MB2) and a RANDOM-MB were used in this
experiment. The hybridization temperatures and specificity of the
MBs were first tested in solution. The fluorescence emission of
these MBs was monitored at temperatures ranging from 25 to
80uC, under different conditions: MB alone, MB in presence of the
specific target, in presence of a non-specific target or in presence of
a plasmid containing BORIS cDNA (pCMV-BORIS). As shown
in Figure S1, noticeable fluorescence signal was detected only
when the MBs were mixed with their specific targets. Optimal
fluorescence emission with acceptable signal-to-background ratio
(.4) was observed below 40uC. The assay also showed that
BORIS-MBs discriminate single and double stranded structures,
since they do not emit fluorescence when incubated with the
pCMV-BORIS plasmid. These results demonstrated that MBs
specifically hybridize to their target sequences and strongly
suggested that these MBs would be able to specifically bind
mRNA and not genomic DNA.
Detection of BORIS mRNA using BORIS-MB
We first verified whether BORIS-MBs could be able to distinguish
positive and negative BORIS expressing cells in living cells.
Quantitative RT-PCR detected strong levels of BORIS mRNA in
NCCIT and OVCAR3 cell lines, whereas this level was very low in
HeLa cells and not detectable in BJ cells (Figure 1A), in accordance
to previous studies [12]. Therefore, to study the specificity of MBs,
NCCIT was used as a positive control cells and BJ as a negative
control. NCCIT cells were transfected with BORIS-MB1 or
BORIS-MB2 and fluorescence emissions were measured by flow
cytometry. The mean fluorescent signals of the cells transfected with
BORIS-MBs were higher compared to the mean fluorescent signal
of the cells transfected with RANDOM-MB. An increase of 23.2 and
4.7 was observed for BORIS-MB1 and BORIS-MB2, respectively
(Figure 1B–C). However, since BORIS-MB1 provided higher (5
fold) mean fluorescence signal compared to BORIS-MB2, BORIS-
MB1 was selected for the subsequent analysis. From here onward
BORIS-MB1 is referred as BORIS-MB. As expected, when BORIS
negative BJ cells were transfected with BORIS-MB, they did not
show any fluorescence signal (Figure 1D).
To further challenge the specificity of the BORIS-MB, HeLa
cells that expressed BORIS mRNA at low level, were transiently
transfected with the pCMV-BORIS expression plasmid, which
contains the human BORIS cDNA fused to green fluorescent
protein (GFP) gene. As expected, the transfected cells presented
high fluorescence signals of both GFP and BORIS (Figure 1E). All
together, these results confirmed the capacity of the BORIS-MB to
reliably and specifically detect BORIS mRNA in living cells.
Hence, the cell lines were transfected with the BORIS-MB to
visualize BORIS mRNA expression by fluorescence imaging. As
can be seen from Figure 1F, the fluorescence signal of BORIS-MB
was clearly visible in NCCIT and OVCAR3 cells, in which only a
subset of cells were fluorescent. The percentage of BORIS positive
cells in these cell lines was found to be between 3 and 5%. As
expected, in BJ normal cell line no fluorescent cells were observed.
In HeLa cells, the number of BORIS positive cells was extremely
low, less than 0.1% (Figure 1E). Overall these experiments
demonstrated that within tumor cell lines, BORIS mRNA is not
present in all cells but rather occurs only in a subset of cells.
Isolation of cell population expressing BORIS mRNA using
BORIS-MB
NCCIT cell line was used for the isolation of BORIS-positive
cells. FACS sorting was performed after cell transfection with
BORIS-MB. The BORIS-positive and BORIS-negative cells
(8.461.5 and 41.567.2% of total, respectively; mean 6 SD) were
sorted (Figure 2A).
BORIS expression analysis showed that BORIS mRNA level of
sorted BORIS-positive cells was 20 fold higher compared to the
non-sorted cells (Figure 2B). This result demonstrated the
efficiency of the sorting method and the successful enrichment of
a cell population that expressed BORIS mRNA.
BORIS/CTCFL in Embryonic Cancer Cells
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The isolated BORIS-positive and BORIS-negative cells
have similar methylation pattern of BORIS promoter B
In a previous study, we have shown that BORIS expression is
controlled by three alternative promoters, corresponding to
transcription start sites at 21447, 2899 and 2658 bp upstream
of the first ATG and designated promoters as A, B and C,
respectively [25]. Interestingly, it has been observed that in
tumors, demethylation of BORIS promoter B, is generally
correlated with the expression of BORIS, which is not the case
for promoters C and A [25]. Consequently, we interrogated the
possible correlation between methylation of promoter B and
BORIS expression in the sorted cells. BORIS methylation level of
this promoter was measured by pyrosequencing, after bisulfite
Figure 1. Detection of BORIS mRNA using BORIS-MB. (A) BORIS expression in human cell lines. Total RNA were isolated from human tumoral
cell lines: NCCIT (embryonic), OVCAR3 (ovarian), HeLa (cervical) and normal BJ (fibroblast) cells. mRNA levels of BORIS were analyzed by qRT-PCR.
Results were normalized to GAPDH and related to NCCIT cells. BJ and NCCIT were considered as negative and positive controls, respectively. Error bars
represent the mean 6 SD of 3 independent experiments. (B) Fluorescent signals measured by flow cytometry of NCCIT cells transfected with
ATTO647-BORIS-MB1 (dark grey peak) and with ATTO647-RANDOM-MB (white peak). (C) Fluorescent signals measured by flow cytometry of NCCIT
cells transfected with ATTO647-BORIS-MB2 (weak grey peak) and with ATTO647-RANDOM-MB (white peak). (D) Fluorescent signals measured by flow
cytometry of BJ cells treated with ATTO647-BORIS-MB1 (from here onward referred to BORIS-MB, grey peak) and with ATTO647-RANDOM-MB (white
peak). (E) BORIS expression in HeLa cells using BORIS-MB. Representative images of HeLa cells transiently transfected with the BORIS expression
vector, pCMV-BORIS (bottom) and non-transfected control cells (top), 206magnification. (F) BORIS expression in human cell lines as detected using
BORIS-MB. Representative images of BJ, NCCIT and OVCAR3 cells, 206magnification. For fluorescence imaging, 16106 cells were incubated at 37uC
for 1 hour in serum-free DMEM medium with Cy3-BORIS-MB (200 nM). Hoechst 33342 5 mg/mL was added during the last 10 min of incubation.
Slides were analyzed by fluorescence microscopy.
doi:10.1371/journal.pone.0109921.g001
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modification of DNA extracted from BORIS-positive and BORIS-
negative cells. Pyrosequencing results indicated that in both
fractions, the CpGs were heavily methylated (85–100% methyl-
ation) and no differences were detected (Figure 3A). This
confirmed that in NCCIT cells, BORIS expression was not
regulated by promoter B and suggested that the different
expression of BORIS among the sorted fractions was not guided
by DNA methylation status of promoter B but rather involved
other levels of control.
BORIS-positive cells express higher mRNA levels of hTERT
as well as stem cell and cancer stem cell markers genes
We previously established that BORIS binds hTERT promoter
at the same site of CTCF and can activate hTERT transcription in
NCCIT cells [12]. To further investigate the correlation between
BORIS, hTERT and CTCF expression, BORIS-positive and
BORIS-negative populations were sorted as mentioned above and
the expression of these genes was evaluated by qRT-PCR.
Interestingly, three independent sorting experiments showed that
hTERTmRNA level was significant higher (from 3.5 to 3.8 fold) in
the BORIS-positive population compared to the BORIS-negative
population. This result confirmed the positive correlation between
BORIS and hTERT expression, whereas no difference was
observed for CTCF (Figure 3B).
Expression of hTERT has been frequently associated with
expression of stemness-related markers [13-17]. Consequently,
considering our results, we also investigated if this correlation
could exist with BORIS expression. To assess this, a panel of
representative genes considered as stemness markers (NANOG,
OCT4, SOX2 and BMI1) or as specific cancer stem cell (CSC)
markers (ABCG2, CD44 and ALDH1) [27] were analyzed by
qRT-PCR. Interestingly, it emerged that the BORIS-positive/
hTERT-high population also expressed higher levels of stem cell-
like markers. Indeed, mRNA levels of mostly all these genes were
significantly higher in BORIS-positive population compared to
BORIS-negative population and non-sorted cells (between 2 and 6
fold in average), at exception of BMI1 and ABCG2 genes
(Figure 3B).
Knockdown of BORIS down-regulates expression of CTCF,
hTERT, stem cell and CSC markers genes
To investigate more directly the functions of BORIS, stable cell
lines with inducible expressing shRNAs, targeting human BORIS
mRNA, were generated using a lentiviral system. Four different
BORIS shRNA lentivirus (BORIS sh-1, sh-2, sh-3 and sh-4) and a
lentivirus carrying a scrambled sequence (CTR sh) were produced
and tested. A significant reduction of BORIS mRNA was observed
in all BORIS-depleted NCCIT-derived cells, compared to control
cells (Figure 4A). The western-blot analysis indicated a remarkable
decrease of BORIS protein level in BORIS sh-3 and sh-4 cells
(Figure 4B). Therefore, all following knockdown experiments were
performed using these BORIS sh-3 and sh-4 NCCIT-derived cells.
The capacity of doxycycline-induction to maintain BORIS-
knockdown overtime was also verified. As shown in figure 5A,
BORIS mRNA levels were significantly reduced during 1 month.
Interestingly, CTCF expression was dramatically decreased
(Figure 5B). As expected, hTERT expression was down-regulated
compared to control (Figure 5C) and this down-regulation was
even stronger after 3 weeks. This observation was consistent with
the correlation observed in the sorting experiments (Figure 3A)
and was further confirmed by telomerase activity analysis. Indeed,
we observed that telomerase activity was also decreased, especially
after 3 and 4 weeks of BORIS silencing (Figure 5D). Notably,
absence of BORIS triggered a dramatic down-regulation (between
75% and 99%) of the expression of stem cell and CSC marker
genes (Figure 5E). This down-regulation was consistent up to the
third week (data not shown).
All these results confirmed that BORIS regulates hTERT and
strongly suggested that BORIS affects the transcription of stem cell
and CSC marker genes, a pattern of genes expressed in CSCs.
Knockdown of BORIS inhibits cell proliferation through
cellular senescence
The impact of BORIS silencing on cell survival of embryonic
tumor cells was also investigated. Cell proliferation was measured
each week during 1 month by MTT assay (Figure 6A). An
inhibition of cell growth was observed starting from the second
week with 26% of reduction, to the fourth week with 40% of
Figure 2. Isolation of BORIS-positive cells using BORIS-MB. (A) NCCIT cells were transfected with ATTO647-RANDOM-MB (white peak) and
ATTO647-BORIS-MB (grey peak). The two subpopulations, BORIS-negative and BORIS-positive cells were selected by comparing the fluorescent signal
of RANDOM-MB to that of BORIS-MB. After exclusion of dead cells by PI staining, the two fractions were sorted. (B) BORIS expression of the isolated
BORIS-negative and BORIS-positive fractions was analyzed by qRT-PCR. The results were normalized to GAPDH and related to non-sorted NCCIT cells.
Error bars represent the mean 6 SD of 3 independent experiments. Asterisk indicates statistically significant difference (p,0.05) between BORIS-
positive and non-sorted cells.
doi:10.1371/journal.pone.0109921.g002
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decrease compared to control. The analysis of apoptosis showed
that the percentage of apoptotic cells (late apoptotic AnnexinV+/
7AAD+ and early apoptotic AnnexinV+/7AAD2) was not
significantly different between BORIS knockdown cells and
control cells (Figure 6B). This result suggested that the decreasing
of the observed cell growth is not due to cell apoptosis, therefore
we further explored the causes of proliferation defects. As BORIS-
knockdown led to a reduction of hTERT expression, a possible
alteration of cellular senescence was investigated. Interestingly,
analysis of senescence-associated b-galactosidase showed that, after
4 weeks of BORIS-knockdown, the percentage of senescent cells
was 2 fold higher in BORIS silenced cells compared to control
cells (Figure 6C). The percentage of senescent cells increased from
5.1 6 1.7% in control cells to 11.962.3% and 9.862.2% in
BORIS silenced with sh-3 and sh-4, respectively. These results
indicated that BORIS knockdown led to the increase of cellular
senescence in embryonic cancer cells.
Discussion
Our study showed that in embryonic tumor cell lines, BORIS
positive cells represent only a subset of the tumor cell population
and the estimated frequency is approximately 3–5% of the total
cells. This observation was confirmed by performing experiments
with BORIS mRNA-targeting MB. Molecular beacon technology
provides a powerful tool to discriminate target sequences, with
very high specificity. Since their discovery [28], the MBs have
been seen to distinguish target sequences differing only by a single
nucleotide. Due to the characteristics of exceptional specificity and
high sensibility, MBs have found a wide range of applications in
biological sciences. MBs were used as taqman probes in real time
quantitative PCR, for detection of mutations, SNP and allele, as
indicators of contaminating infectious agents and also for in vivo
detection of mRNA [29]. Furthermore, MBs are able to bind
target sequences without modifying the functional and genomic
characteristics of the cells. To date, there is no yet a validated
Figure 3. BORIS promoter methylation and expression of hTERT, stem cell and CSC markers genes in BORIS-positive cells. (A)
Methylation analysis of 10 CpG islands within the BORIS promoter region (B promoter). The representative graphic shows the percentage of
methylation of each CpG island for the isolated BORIS-positive (white), -negative (grey) and non-sorted (black) NCCIT cells. (B) Expression analysis of
the isolated BORIS-positive (white) and BORIS-negative (grey) fractions. The indicated genes were analyzed by qRT-PCR. The results were normalized
to GAPDH and related to non-sorted NCCIT cells. Graphic shown one representative experiment out of 3 independent experiments (the trend was
similar in all independent experiments). Asterisks indicate statistically significant difference (p,0.05) between BORIS-positive and the non-sorted
cells.
doi:10.1371/journal.pone.0109921.g003
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antibody for in vivo detection of BORIS, therefore we used the
MB technology to visualize BORIS mRNA positive cells.
Recently, two publications demonstrated the use of MBs in FACS
sorting [30,31]. However, they showed different delivery systems
of MBs to enter into the cells. One group described a delivery
system with a cationic lipid vehicle [30] and the other group used
electroporation with a dual-FRET MB [31]. Instead, we used the
RNAiMAX Transfection Reagent, a cationic lipid formulation
that was designed specifically for delivery single strand nucleotides
(siRNA and miRNA). Additionally, we used for the sorting
experiments, BORIS-MB conjugated with ATTO647, a fluor-
ophore which confers a high photostability of fluorescence signal
[20]. The analysis of BORIS expression demonstrated that we
successfully enriched the cell population that expressed BORIS
mRNA. In our experiments we used NCCIT cell line, classified as
germ-cell tumor or embryonic cancer cells [32]. Due to its higher
BORIS expression compared to the other tumor cell lines, the
NCCIT cell line provides a good model for our studies, especially
for the feasibility of isolation of BORIS positive cells by MB
technology.
In a previous study, we have shown that BORIS modulates the
transcription of hTERT telomerase gene in NCCIT and
OVCAR3 cells, and in opposite manner compared to its paralog
CTCF [12]. To further investigate the correlation between
BORIS, hTERT and CTCF, we analyzed their expression in
FACS-isolated BORIS-positive and BORIS-negative cells. The
results confirmed the positive correlation between BORIS and
hTERT, whereas no correlation was observed with CTCF. In the
same previous work, it has been found that ectopic BORIS
expression in normal BORIS negative cells allowed to expand the
in vitro lifespan increasing cell passages. This finding could be
explained by the expression of high levels of hTERT mRNA in
these BORIS-transfected cells. Induction of hTERT expression
and telomerase activity are well established as hallmarks of cancer
and are prerequisite to cellular immortalization and malignant
transformation [33]. Here, we confirm the role of BORIS in the
immortalization process during tumorigenesis, since the isolated
BORIS-positive cells expressed significantly higher levels of
hTERT mRNA compared to the counterpart BORIS-negative
cells.
In normal human cells, telomerase is generally absent in somatic
cells but remains active in germ cells, progenitor cells and some
adult stem cells [14]. It has been shown that telomerase is
reactivated in a majority (approximately 90%) of tumors [34] and
in clinical studies its reactivation is associated with poor outcomes
of different tumors [35–38]. In addition, current literature
supports the evidence that CSCs express telomerase and its
inhibition suppresses the self-renewal of CSCs [39–41]. All these
Figure 4. BORIS-knockdown using lentivirus with doxycycline inducible BORIS-specific shRNA. Four different BORIS shRNA lentiviral
vectors (BORIS sh-1, sh-2, sh-3 and sh-4) and the vector carrying a scrambled sequence (CTR sh) were tested. NCCIT were transduced with the
indicated lentivirus and sorted for eGFP marker expression. Then, cells were cultured with doxycycline-containing medium and after 3 days were
analyzed. (A) BORIS mRNA levels were determined by qRT-PCR analysis, normalized to GAPDH and compared to that of CTR sh. Error bars represent
the mean 6 SD of 3 independent experiments. Asterisks indicate statistically significant difference (p,0.05) between BORIS sh-1, sh-2, sh-3 or sh-4
and CTR sh cells. (B) Representative western blot analysis. BORIS and b-actin (as a loading control) protein levels were determined by western blot.
For both analyses (qRT-PCR and western blot) the knockdown was especially noticed with the BORIS sh-3 and sh-4 compared to the CTR shRNA.
doi:10.1371/journal.pone.0109921.g004
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discoveries, together with our observations, indicate that BORIS
could play an important and direct role in tumor malignancies by
up-regulation of the hTERT telomerase gene. Consistent with this,
we notably observed that the BORIS-positive/hTERT-high
isolated cells expressed also high levels of the most important
stem cell markers. The embryonic carcinoma cells that we
investigated, indeed, provide a good model system to study the
stem cell concept of cancer. They are stem cells derived from a
teratocarcinoma and are also the malignant transformed embry-
onic stem cells [42]. They show gene expression profiles close to
those of human embryonic stem cells [43]. Therefore, we analyzed
the association of BORIS-positive/hTERT-high cells with the
expression of the key-regulator genes of embryonic cells (NANOG,
SOX2 and OCT4) and with some of the most known specific
Figure 5. Knockdown of BORIS resulted in decreasing expression of hTERT, stem cell and CSC markers genes. NCCIT cells were
engineered to stably exhibit knocked-down BORIS mRNA. BORIS sh-3, sh-4 and CTR sh (control with scrambled sequence) lentivirus were used to
infect NCCIT cells. Each transduced cells were cultured with doxycycline to induce BORIS shRNA expression. Doxycycline-containing medium was
replaced every 3 days. Each week over 1 month, mRNA levels of (A) BORIS, (B) CTCF and (C) hTERT were analyzed by qRT-PCR. Results were normalized
with GAPDH and related to that of control cells (CTR sh) at each week. Error bars represent the mean 6 SD of 3 independent experiments. (D)
Telomerase activity was measured at each week by real-time quantitative PCR using TRAPEZE RT Telomerase Detection Kit. Values of telomerase
activity of BORIS sh-3, sh-4 NCCIT-derived cells are related to that of control cells at each week. Error bars represent the mean6 SD of 3 independent
experiments. (E) BORIS sh-3, sh-4 and CTR sh NCCIT-derived cells were cultured with doxycycline and after 7 days RNA was analyzed by qRT-PCR.
mRNA levels of the indicated genes are related to that of control cells (CTR sh) after normalization with GAPDH. Error bars represent the mean6 SD of
3 independent experiments. Asterisks indicate statistically significant difference (p,0.05) between BORIS sh-3 or BORIS sh-4 and CTR sh cells.
doi:10.1371/journal.pone.0109921.g005
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Figure 6. BORIS knockdown impairs cell senescence but not apoptosis. (A) Cell proliferation over 1 moth of dox-induced BORIS shRNA cells
were analyzed by MTT assay. Results of the two specific BORIS-shRNA (BORIS sh-3 and sh-4) NCCIT-derived cells are indicated as a percentage
compared to the cell proliferation of control cells (scrambled shRNA, CTR sh). Error bars represent the mean 6 SD of 3 independent experiments. (B)
After dox-induction of the BORIS specific shRNA in NCCIT cells, apoptosis was tested at each week using Annexin V Apoptosis Detection Kit. Results
show the percentage of apoptotic cells (late apoptotic AnnexinV+/7AAD+ and early apoptotic AnnexinV+/7AAD2) of BORIS sh-3 and sh-4 cells
compared to the control cells. Error bars represent the mean 6 SD of 3 experiments. (C) The senescence-associated b-galactosidase (SA-b-gal)
staining was performed using b-galactosidase staining kit. SA-b-gal was analyzed after 2 and 4 weeks of dox-induction of the BORIS specific shRNA in
NCCIT cells. Results show the percentage of senescent cells of BORIS sh-3, BORIS sh4 and control cells. Error bars represent the mean 6 SD of 3
experiments. Asterisks indicate statistically significant difference (p,0.05) between BORIS sh-3 or BORIS sh-4 and CTR sh cells. Representative images
of NCCIT cells after 4 weeks of BORIS knockdown and stained with SA-b-gal were shown.
doi:10.1371/journal.pone.0109921.g006
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markers of CSCs [27]. CSCs are cancer cells characterized by
stem cell properties and represent a small population of tumor cells
that drives tumor development, progression, metastasis and drug
resistance [27]. Interestingly, a correlation of the isolated BORIS-
positive/hTERT-high cells with high expression of stem cell
markers was observed. These findings were confirmed by BORIS
silencing studies. Stable BORIS knockdown NCCIT-derived cells
were generated by an efficient system of inducible-shRNA
lentivirus [21]. After BORIS silencing, a significant decrease of
hTERT expression was observed, as well as a down-regulation of
telomerase activity, which is strictly regulated by hTERT gene
transcription. CTCF expression was also decreased. This is
consistent with our previous results [12] and confirms a role of
BORIS in the transcriptional regulation of CTCF. This correlation
between CTCF and BORIS was not observed in the expression
analysis of the isolated BORIS-positive cells. This discrepancy
could be due to the different experimental conditions. Indeed, in
the expression analysis of the isolated BORIS-positive cells, CTCF
was analyzed at steady state, while in BORIS silencing studies
what we observed is the result of cellular and genetic modifica-
tions.
Importantly, after BORIS knockdown a decrease of expression
of stem cell and CSC marker genes (NANOG, OCT4, SOX2,
BMI1, ABCG2, CD44 and ALDH1) was also observed. These
results highlight the importance of BORIS in malignant disease
and its possible critical role on cancer growth and progression.
Previous works have already showed a correlation of BORIS with
stem cells. Monk et al. have observed the co-localization at the
protein level of BORIS with ECSA, OCT4 and NANOG in
cultured embryonic stem cells [44]. John et al. have detected
BORIS expression in ECSA-expressing lung tumors [45]. In this
paper, we additionally showed the molecular function of BORIS
in embryonic cancer cells and all these data strongly suggested that
BORIS affects the expression of stem cell genes.
Cell proliferation analysis revealed that the depletion of BORIS
led to cell growth inhibition and an increase of cellular senescence
in embryonic cancer cells. Cellular senescence is defined as the
irreversible arrest of cell growth that is activated after alteration of
telomeres or in response to different forms of stress [46]. Of note,
cellular senescence is considered as a potent tumor suppressive
mechanism, a protective barrier against neoplastic expansion [47].
Senescent cells cannot divide, even if they continue to be
metabolically and synthetically active [48]. Senescent cells also
show changes in chromatin organization and gene expression [49].
In our studies, the cellular senescence was measure by the most
widely used senescence associated marker, the aˆ-galactosidase
activity [50]. The increasing of senescent cells after BORIS
knockdown could be caused by the simultaneous telomerase
inhibition. Consistent with the finding that inhibition of telomerase
has been shown to initiate telomere shortening followed by cell
senescence and cell death by apoptosis [51,52].
In summary, the present study provides evidences that BORIS
is only expressed in a small subset of tumor cells in embryonic
tumors. As BORIS affects the expression of stemness-related
genes, this subpopulation of BORIS positive cells might play an
important role in cancer growth and progression. Our findings
provide a rationale for investigating therapies that target BORIS/
CTCFL in embryonic tumors.
Supporting Information
Figure S1 Fluorescence emission profiles of MBs.
Representative fluorescence emission profiles of BORIS-MB1,
BORIS-MB2 and RANDOM-MB. All the MBs were 59-end Cy3-
conjugated. All thermal profiles indicate the MBs (200 nM) alone
(green dash line) and MBs mixed with specific target (red solid
line), with non-specific target (black dash-dot line) and with
plasmid (pCMV-BORIS, blue dot line). The targets were used at
the final concentration of 1 mM. The samples were analyzed by
Rotor Gene 6000 Real-Time PCR system and the fluorescence
was measured at each temperature (from 25uC to 80uC) using filter
for Cy3.
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